Supported by CCR Office of Science and Technology Resources (OSTR)




MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma.

Yohe, M. E., et. al.

PubMed Link

M7824, a novel bifunctional anti-PD-L1/TGFbeta Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine.

Knudson, K. M., et. al.

PubMed Link

Synthesis and Biological Evaluation of Fluorescent Bryostatin Analogues.

Cummins, T. J., et. al.

PubMed Link


Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation.

Simmons, J. K., et. al.

PubMed Link


Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer.

Noonan, A. M., et al.

PubMed Link

A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma.

Holkova, B., et al.

PubMed Link

RCC1-dependent activation of Ran accelerates cell cycle and DNA repair, inhibiting DNA damage-induced cell senescence.

Cekan, P., et al.

PubMed Link

Small Molecule Microarrays Enable the Identification of a Selective, Quadruplex-Binding Inhibitor of MYC Expression.

Felsenstein, K. M., et al.

PubMed Link

Genomic profiling of multiple sequentially acquired tumor metastatic sites from an “exceptional responder” lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response.

Biswas, R., et. al.

PubMed Link

Liver Label Retaining Cancer Cells Are Relatively Resistant to the Reported Anti-Cancer Stem Cell Drug Metformin.

Xin, H. W., et. al.

PubMed Link

Biological activity of the bryostatin analog Merle 23 on mouse epidermal cells and mouse skin.

Kelsey, J. S., et. al.

PubMed Link

Quantitation of TGF-beta proteins in mouse tissues shows reciprocal changes in TGF-beta1 and TGF-beta3 in normal vs neoplastic mammary epithelium.

Flanders, K. C., et. al.

PubMed Link

Cell autonomous or systemic EGFR blockade alters the immune-environment in squamous cell carcinomas.

Mascia, F., et. al.

PubMed Link